ANTIMICROBIAL LOCKING SOLUTIONS COMPRISING TAURINAMIDE DERIVATIVES AND BIOLOGICALLY ACCEPTABLE SALTS AND ACIDS, WITH THE ADDITION OF SMALL CONCENTRATIONS OF HEPARIN
The present invention relates to inhibiting or preventing infection and protecting against patency complications after a blood catheter has been inserted in a patient comprising administering to the device a pharmaceutically effective amount of a composition comprising: (A) at least one taurinamide derivative, (B) at least one compound selected from the group consisting of biologically acceptable acids and biologically acceptable salts thereof; and (C) heparin at a low concentration.
1 .- 24 . (canceled)
25 . A locking solution for treating and reducing infection and flow reduction in blood catheters, the locking solution comprising:
at least one taurinamide derivative; and
heparin in a concentration of 50 to 2500 units per mL.
26 . The locking solution according to claim 25 wherein the taurinamide derivative is taurolidine.
27 . The locking solution according to claim 25 further comprising a biologically acceptable acid.
28 . The locking solution according to claim 27 wherein the biologically acceptable acid is chosen from the group consisting of citric acid and lactic acid.
29 . The locking solution according to claim 27 wherein the taurinamide derivative is taurolidine and the biologically acceptable acid is citric acid.
30 . The locking solution according to claim 28 further comprising a biologically acceptable salt of the biologically acceptable acid.
31 . The locking solution according to claim 30 wherein the biologically acceptable salt is chosen from the group consisting of citrate and lactate.
32 . The locking solution according to claim 25 wherein heparin is in a concentration of 50 to 1750 units per mL.
33 . The locking solution according to claim 25 wherein heparin is in a concentration of 50 to 500 units per mL.
34 . The locking solution according to claim 25 wherein heparin is in a concentration of 50 to 150 units per mL.
35 . A method for treating and reducing infection and flow reduction in blood catheters, the method comprising:
providing a blood catheter with a catheter locking solution comprising taurolidine and heparin in a concentration of 50 to 2500 units per mL.
36 . The method according to claim 35 wherein the taurinamide derivative is taurolidine.
37 . The method according to claim 35 wherein the locking solution further comprises a biologically acceptable acid.
38 . The method according to claim 37 wherein the biologically acceptable acid is chosen from the group consisting of citric acid and lactic acid.
39 . The method according to claim 37 wherein the taurinamide derivative is taurolidine and the biologically acceptable acid is citric acid.
40 . A composition for treating and reducing infection and flow reduction in hemodialysis catheters, the composition comprising:
at least one taurinamide derivative; and
heparin in a concentration of 50 to 2500 units per mL.
41 . The composition according to claim 40 wherein the taurinamide derivative is taurolidine.
42 . The composition according to claim 40 further comprising a biologically acceptable acid.
43 . The composition according to claim 42 wherein the biologically acceptable acid is chosen from the group consisting of citric acid and lactic acid.
44 . The composition according to claim 42 wherein the taurinamide derivative is taurolidine and the biologically acceptable acid is citric acid.
45 . A locking solution for treating and reducing infection and flow reduction in catheters, the locking solution comprising:
at least one taurinamide derivative;
a biologically acceptable acid in a concentration that brings the pH of the locking solution into a range of 5.2 to 6.5; and
heparin in a concentration of 50 to 2500 units per ml.
46 . The locking solution according to claim 45 wherein the taurinamide derivative is taurolidine.
47 . The locking solution according to claim 45 wherein the biologically acceptable acid is chosen from the group consisting of citric acid and lactic acid.
48 . The locking solution according to claim 45 wherein the taurinamide derivative is taurolidine and the biologically acceptable acid is citric acid.